The core mechanism lies in its ability to metabolize tryptophan to produce Indole-3-carboxaldehyde (I3C). As an activator of the Aryl Hydrocarbon Receptor (AHR) signaling pathway, I3C helps modulate abnormal Th2-type immune responses, thereby addressing skin inflammation at its root.
This mechanism is supported by rigorous clinical research and patents. Studies confirm that CCFM1029 helps reshape the gut microbiome and significantly increases I3C levels in the body. Clinical trials have demonstrated its effectiveness in reducing the SCORAD (SCORing Atopic Dermatitis) index, with symptom alleviation showing a significant negative correlation with elevated I3C levels.
To ensure optimal efficacy, the product utilizes advanced 5-layer microencapsulation technology, which guarantees high survival rates of live bacteria and precise delivery to the intestines. Combined with our comprehensive one-stop OEM/ODM services, we can help you rapidly develop premium skin health products.